ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference

Jul 01, 2015, 16:05 ET from ContraVir Pharmaceuticals, Inc.

EDISON, N.J., July 1, 2015 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Cantor Fitzgerald Inaugural Healthcare Conference taking place in New York, NY on July 8, 2015 at Le Parker Meridien Hotel.

James Sapirstein, Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event:

Cantor Fitzgerald Inaugural Healthcare Conference

Date: 

Wednesday, July 8, 2015

Time: 

11:15am (Eastern Time)

Location:

Le Parker Meridien Hotel, New York, NY

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®), for the Hepatitis B virus (HBV) in Phase 2 clinical studies.  CMX157 is active against HBV and more than 4 times more potent in vitro versus tenofovir.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  

For further information, please contact:

Tiberend Strategic Advisors, Inc. 

Tirth Patel (investors)  tpatel@tiberend.com; (212) 375-2681

Claire Sojda (media)  csojda@tiberend.com; (212) 375-2686

 

SOURCE ContraVir Pharmaceuticals, Inc.